Sonexa Therapeutics was incorporated in January 2008.
Sonexa Therapeutics, Inc., is a privately-held pharmaceutical company committed to the development of drug treatments for Alzheimer's Disease (AD) and related disorders. On January 31, 2008, it was announced that it had raised $30 million in a Series A round of financing.
ST101, our lead compound, represents a first-in-class agent that, in animal models, has demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. ST101 has completed Phase I studies in both healthy volunteers and AD patients and has successfully completed Phase II Proof-of-Concept trials.
AD is a progressive, incurable disease. Nearly 30 million people currently have AD and it is estimated that by the year 2050 over 100 million people will fall victim to this disorder. AD patients have abnormally high brain accumulation of certain proteins, including beta amyloid and tau. Protein accumulation may impede normal transmission of chemical signals in the brain causing cognitive impairment. It may also produce cell death, leading to a reduction in functional brain mass. Marketed treatments provide some symptomatic improvement in memory and related signs, but do not stop or reverse the underlying pathology.